Considering that up to 50% of JDM patients fail first-line therapies there remains an urgent need for new, more targeted treatments.69–71 Thus, the identification of a novel, ‘druggable’ target that modulates the IFN type 1 signature has broad implications for the development of new treatment strategies in JDM and potentially other IFN-driven disorders. Here, IFNA1 is linked to juvenile dermatomyositis.